A bull market will eventually follow the challenging and volatile times we face, and, based on history, this bull run is ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older ...

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

The company’s portfolio includes two products: Covid-19 vaccine and RSV vaccine (approved only in May 2024). However the company does have a promising pipeline. Moderna has shown promising ...

Healthcare & Pharmaceuticalscategory· February 28, 2025 UK health regulator approves Moderna's RSV vaccine for adults aged 60 and older Britain's health regulator said on Friday it has approved ...